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To eradicate the Hepatitis C Virus from the bodies of the infected individuals 
Interferon and Ribavirin based therapy is used. HCV is highly prevalent in 
District Mardan Khyber Pakhtunkhwa that is why it is important to 
determine the response of standard interferon based therapy in Chronic HCV 
patients of this region. A total of 215 patients were selected for interferon 
based therapy. The patients were selected from three different Tehsil of 
District Mardan. After confirmation of active HCV infection by q-PCR, 
standard interferon with Ribavirin was given to patients for 6 months. After 
completion of therapy, end of treatment virologic response (ETR) was 
calculated. After completion of the 6 months long therapy, the results 
obtained were as. Out of total 215 patients, 168 (78.13%) were negative for 
HCV RNA and showing end of treatment response (ETR) while 47 (21.86%) 
were positive for HCV RNA and did not show ETR. In Tehsil Mardan, out 
of 102 patients who had completed therapy, 76 patients (74.51%) showed 
ETR and 26 (25.49%) did not show the ETR. In Tehsil Kattlang, we found 
that out of total 51 patients who had taken 6 months therapy, 41 (80.39%) 
were negative for HCV RNA and 10 (19.61%) were resistant to therapy 
while in Tehsil Tkhatbhai, out of 62, 50 (80.64%) were negative and 12 
(19.35%) were positive. The above discussion shows that antiviral therapy 
against HCV infection in chronic HCV patients of District Mardan KPK 
province is 78.13%. The high response rate may be due to the prevalence of 
genotypes 2 and 3. 




Hepatitis C virus,  most important public health 
problem and leading cause of liver infection and 
affected an estimated 180 million people worldwide 
(William, 2006). Its genome consists of a single 
stranded, positive-sense RNA which was of 9600 bp 
long and encoding single ployprotein. 
Epidemiological studies showed that HCV infection 
increases annually more then one million new cases 
are reported. Among all type of Hepatitis, HCV is 
more than other type’s infection i-e HBV (Cooreman 
and schoondermark, 1996). Their major associated 
problems are the leading cause of liver 
transplantation and organ storage. The introduction of 
effective therapy for the prevention of life threatening 
diseases is the vital target. Its especially most 
important in underdeveloped countries, Where HCV 
infection is more and most of the infected patients 
have financial problems for the treatment of HCV 
infection (Ahmad et al., 2012). 
Major purpose of Hepatitis treatment is to eradication 
the virus that is Sustained virologic response (SVR) 
Which is defined as absence of HCV in serum after 
six months of treatment completion and evidenced 
through polymerase chain reaction (PCR) tests, when 
treatment strategies have been shifted from interferon 
monotherapy to combined interferon plus Ribavirin a 
great improvement in the SVR rates have been 
observed by the past so many years (Muhutchison et 
al., 1998; Poynardn et al., 1998). 




Hepatitis C therapy started almost 25 year ago with a 
small trial of recombinant human interferon Alfa 
(Hoofnagle et al., 1986). Interferon has broad 
spectrum activities so that why it was selected against 
the viruses and it might also be active against still 
undiscovered non-A and non-B hepatitis. Interferon 
was found very active against HCV and resultant 
effects were decrease the level of ALT. Before the 
discovery of the HCV the effects of interferon was 
unknown but the result of using the interferon was 
the reduction in HCV RNA level. This led to SVR in 
patients of HCV (Hoofnagle and Seeff, 2006). 
Ribavirin a nucleoside analogue, known to have 
activity against a number of flaviviruses had strong 
effects in lowering the level of ALT and little effects 
on serum HCV RNA levels. Besides that when 
Ribavirin and interferon was given in combination 
for 48 weeks then it has increased sustained virologic 
response rate, then sustained virologic response rates 
was 40-50% which is two to three times more than 
that obtained with interferon alone (Dibiceglie et al., 
1995; Muhutchison et al., 1998). When Ribavirin 
combined with Pegylated interferon it response rate 
has better than standard interferon (Fried et al., 
2002). 
Standard interferon therapy is use in Pakistan, due to 
economic reasons and Pakistan Society of 
Gastroenterology and GI Endoscopy also favours the 
use of SdIF in genotype-3 (Hamid et al., 2004). PgIF 
is out of reach for the majority of the patients because 
the Government of Pakistan is providing only SdIF 
via a special Prime Minister's initiative programme 
against hepatitis, thus. Response rates of standard 
interferon in chronic HCV patients have never been 
investigated in District Mardan, KPK. The study had 
focused on the effectiveness of standard interferon 
therapy as given in the case of chronic HCV patients 
in District Mardan, Khyber Pakhtunkhwa province of 
Pakistan. 
 
Material and Methods 
 
Present study was conducted at District Head Quarter 
Hospital, Mardan (DHQ) in collaboration with 
Provincial program for Hepatitis Control and 
Prevention.  
To assess the response of standard interferon 
combination therapy against chronic HCV infection, 
we selected three different regions/Tehsil of District 
Mardan, KPK province. The regions were Tehsil 
Kattlang, Mardan and Tehsil Tkhatbhai. In present 
study, patients with suspected liver disease were 
included who were referred to Head Quarter 
Hospital, Mardan (DHQ) from three Tehsil of 
Mardan District during June 2012 to January 2013 in 
the Provincial Program for Control and Prevention of 
Hepatitis which provides molecular based diagnostic 
facility that general public sensitive, specific and 
more reliable diagnostic tests on the basis of utilizing 
PCR and real-time PCR methods and Hepatitis 
treatment (Standred interferon therapy). After initial 
screening with ICT (ACON, USA) and Elisa assay 
kit (Glibe Diagnostics, ITALY), PCR test was 
performed for each patient sample according to the 
instructions of the manufacturers (Gibco BRL, Life 
Technologies USA). Among the confirmed anti-HCV 
patients, only 215 patients whose PCR was positive, 
were selected for interferon therapy keeping in mind 
the exclusive therapy criteria that is, age of the 
selected personals (18-55 years), platelets and Hb 
levels within the accepted range, stage of cirrhosis, 
no co-infection associated and ALT level higher than 
normal. We selected 102 patients from Tehsil 
Mardan, 62 from Tehsil Tkhatbhai and 51 patients 
from Tehsil Kattlang. There was no need for separate 
written informed consent from subjects for this study, 
since this analysis was a part of the original protocol 
in a routine workup of Molecular Diagnosis and 
Treatment. 
PCR positive patients were given standard interferon 
combination therapy i.e. interferon alpha 2a (3MIU 
thrice a week) plus Ribavirin (1000-1200 mg/day) 
continuously for 6 months with repeated testing of 
ALT level and HCV RNA during and after the 
interferon therapy. 
 
Statistical Analysis & Graphical representation  
Statistical Analysis for the calculation of percentage 
and distribution of the samples in different groups, 





After completion of the 6 months long therapy, the 
results obtained were as. Out of total 215 patients, 
168 (78.13%) were negative for HCV RNA and 
showing end of treatment response (ETR) while 47 
(21.86%) were positive for HCV RNA and did not 
show ETR. In Tehsil Mardan, out of 102 patients 
who had completed therapy, 76 patients (74.51%) 
showed ETR and 26 (25.49%) did not show the ETR. 
In Tehsil Kattlang, we found that out of total 51 
patients who had taken 6 months therapy, 41 
(80.39%) were negative for HCV RNA and 10 
(19.61%) were resistant to therapy while in Tehsil 
Tkhatbhai, out of 62, 50 (80.64%) were negative and 
12 (19.35%) were positive. (Table 1). 
 
Table 1: Tehsil wise distribution of HCV positive sample and their respective ETR 














Mardan 102 19-52 80 22 76 26 74.51 25.49 
Kattlang 51 18-55 36 15 41 10 80.39 19.61 
Tkhatbhai 62 21-54 51 11 50 12 80.64 19.35 
Total 215  167 48 167 48 78.13 21.86  
 
Figure 1. Tehsil wise Percentage of ETR Bar 
 
 
Our study revealed that response rate of combination 
therapy was comparatively higher in Tehsil 
Tkhatbhai (89.64%), Tehsil Kattlang (89.39%) and 
than in Tehsil Mardan (74.51%). The percent 




Hepatitis C Virus infection is scattering very 
speedily. HCV incidence is nearly 200 million people 
worldwide and each year infects 3-4 million new 
people (Yvan et al., 2004). The seroprevalence of 
Hepatitis C virus reported from different parts of 
Pakistan, in last 5 years, is from 2.2%-13.5%. The 
highest seroprevalence of hepatitis C has been 
reported from Lahore (13.5%) (Amin et al., 2004) 
Jasmshoro (9%) and Mardan (9%) (Almani et al., 
2002; Khan et al., 2004). 
Pakistan is a underdeveloped country and the literacy 
rate is also low, due to which lack of information 
regarding the pathogenecity, routes of transmission 
and the proper procedures of diagnosis proper 
screening facilities or expertise in screening blood 
and blood products for possible HCV infection in 
public sector hospitals is partly contributing towards 
the spreading of the disease and treatment are rarely 
followed. Therefore HCV infection has become an 
economic burden on the people of Pakistan and 
especially in District Mardan KPK. 
In the present study we determined the End of 
Treatment Response (ETR), which may be defined as 
the absence of HCV RNA at the end of 6 months 
Interferon therapy, in CHC patients. The average 
calculated ETR was 78.13% and resistance calculated 
was 21.86%. Different Tehsil of District Mardan 
KPK province had different ETR rates; like ETR was 
very high in Tehsil Tkhatbhai followed by Tehsil 
Kattlang and then Tehsil Mardan [Figure 1]. 
The average response rate of interferon combination 
therapy with Ribavirin in chronic HCV patients of 
District Mardan population was 78.13% [Table 1]. 
Although District Mardan has different population 
groups which may vary regarding response to 
interferon based therapy. Instead, the response rate 




was similar to other studies conducted internationally 
(Mann et al., 2006; Strader et al., 2004) as well as 
locally (Wazir et al., 2002), when combination 
therapy treatment with Ribavirin and interferon. 
In District Mardan prevalence of HCV infection has 
been recorded as 9% (Khan et al., 2004). The high 
ETR rate in district Mardan might be due to the high 
prevalence of HCV genotypes 2 and 3 and might be 
due to high literacy rate, as by adopting proper 
procedures for diagnosis and treatment, the efficacy 
rate might be increased as compared to those who 
have no or little knowledge. 
 
Conclusion 
The above discussion shows that antiviral therapy 
against HCV infection in chronic HCV patients of 
District Mardan KPK province is 78.13%. The high 
response rate may be due to the prevalence of 
genotypes 2 and 3. 
 
Acknowledgement 
We are grateful to the Department of Microbiology 
Hazara University, Mansehra and DHQ hospital, 
Mardan for approving and facilitating this study. We 
are thankful to Mr. Aurangzeb Tubassum Dealing 
assistant HP&C, DHQ Hospital, Mardan for 
providing lab facilities. We also appreciate Dr. 
Kashif Haleem and Dr. Isfahan Dr. Azam Hayyat, 
Miss Nadia Jabeen, Mr. M. Junaid and Muhammad 
Iqbal Ahmad Alvi Department of Microbiology 
Hazara University Mansehra, Pakistan for helpful 




Ahmad, B., Ali, S., Ali, I., Azam, S. and Bashir, S. 
(2012): Response rates of standard interferon therapy 
in chronic HCV patients of Khyber Pakhtunkhwa 
(KPK). Virology Journal., 9:18. 
Almani, S.A., Memon, A.S., Qureshi, A.F. and 
Memon, N.M. (2002): Hepatitis viral status in Sindh. 
Professional. Med. J., 9(1):36-43. 
Amin, J., Yousf, H., Mumtaz, A., Iqbal, M., Ahmed, 
R. and Adhami, S.Z. (2004): Prevalence of Hepatitis 
B surface antigen and Anti Hepatitis C virus. 
Professional. Med. J., 11(3):334-337. 
Cooreman, M.P. and Schoondermark, V.M. (1996): 
Hepatitis C virus. Biological and clinical 
consequences of genetic heterogeneity. Scand J. 
Gastroenterol. Suppl., 218:106-115. 
Dibiceglie, A.M., Conjeevaram, H.S. and Fried, 
M.W. (1995): Ribavirin as therapy for chronic 
hepatitis C: A randomized, double-blind, placebo-
controlled trial. Ann. Intern. Med., 123:897-903. 
Fried, M.W., Shiffman, M.L. and Reddy, K.R. 
(2002): Peg-interferon alfa-2a plus ribavirin for 
chronic hepatitis C virus infection. N. Engl. J. Med., 
347:975-982. 
Hamid, S., Umar, M., Alam, A., Siddiqui, A., 
Qureshi, H. and Butt, J. (2004): PSG consensus 
statement on management of hepatitis C virus 
infection-2003. J. Pak. Med. Assoc., 54:146-150. 
Hoofnagle, J.H. and Seeff, L.B. (2006): Peg-
interferon and ribavirin for chronic hepatitis C. N. 
Engl. J. Med., 355:2444-2451. 
Hoofnagle, J.H., Mullen, K.D. and Jones, D.B. 
(1986): Treatment of chronic non-A, non-B hepatitis 
with recombinant human alpha interferon: a 
preliminary report. N. Engl. J. Med., 315:1575-1578. 
Khan, M.S.A., Khalid, M., Ayub, N. and Javed, M. 
(2004): Seroprevalence and risk factors of Hepatitis 
C virus (HCV) in Mardan: N.W.F.P. Rawal. Med., 
29:57-60. 
Mann, M.P., Wedermayer, H. and Cornberg, M. 
(2006): Treating viral hepatitis C: efficacy, side 
effects, and complications. Gut., 55:1350-1359. 
Muhutchison, J.G., Gordon, S.C. and Schiff, E.R. 
(1998): Interferon alfa-2b alone or in combination 
with ribavirin as initial treatment for chronic hepatitis 
C. N. Engl. J. Med., 339:1485-1492. 
Muhutchison, J.G., Gordon, S.C., Schiff, E.R., 
Shiffman, M.L., Lee, W.M. and Rustgi, V.K. (1998): 
Interferon alfa-2b alone or in combination with 
ribavirin as initial treatment for chronic hepatitis C. 
Hepatitis Interventional Therapy Group. N. Engl. J. 
Med., 339:1485-1492. 
Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., 
Minuk, G.S. and Ideo, G.l. (1998): Randomised trial 
of interferon alpha2b plus ribavirin for 48 weeks or 
for 24 weeks versus interferon alpha2b plus placebo 
for 48 weeks for treatment of chronic infection with 
hepatitis C virus. International Hepatitis 




Interventional Therapy Group (IHIT). Lancet., 
352:1426-1432. 
Strader, D.B., Wright, T. and Thomas, D.L. (2004): 
Diagnosis, management and treatment of hepatitis C. 
Hepatology., 39:1147-1171. 
Wazir, M.S., Majid, A.S., Solangi, G.A. and Zuberi, 
B.F. (2002): Role of interferon and interferon plus 
Ribavirin in the management of chronic hepatitis C. 
J. Coll. Physicians. Surg. Pak., 12:609-612.  
Williams, R. (2006): Global challenges in liver 
disease. Hepatology., 44:521-526. 
Yvan, H., Mary, E.K., Gregory, J.D., Joseph, F.P., 
Gregory, L., Geoffrey, D., Hiromi, I., Peter, G., 
Michael, K., Patrick, M., Leonard, B.S., Philippe, B., 
Christopher, N., Claudia, S., Pascal, Z., Gary, C., 
Robert, V., Alfredo, A., Zuhair, S.H., Stephen, H. 
and Daniel, L. (2004): Global Burden of Disease 
(GBD) for hepatitis C. J. Clin. Pharmacol., 44:20-29. 
 
